Wegovy Day 2: What the Evidence Says About Early Side Effects

Why the timing of day 2 matters: the pharmacokinetics behind the feeling

Understanding what happens in your body on day 2 of Wegovy makes the experience far less alarming. After a subcutaneous injection of semaglutide, the medicine is absorbed gradually from the tissue beneath the skin. Peak plasma concentration is reached somewhere between one and three days post-injection, meaning the second day often coincides with semaglutide reaching its highest level in your system for that week. From there it declines slowly, semaglutide has a half-life of around one week, which is exactly why once-weekly dosing works. The STEP 1 trial, published in the New England Journal of Medicine, enrolled over 1,900 adults and tracked tolerability in detail across the full 68-week period; gastrointestinal events were most frequent at the beginning of treatment and after each dose increase, then diminished. That pattern maps closely onto what people report on their first day: a low-grade unsettled stomach, or sometimes nothing at all, followed by a second day that feels sharper before things begin to improve, something our day 3 Wegovy guide picks up in detail as the first week continues to unfold.

The 0.25 mg starting dose exists specifically to give the body time to adjust. It is not the dose at which meaningful weight loss is expected; that comes as the prescriber moves the schedule upward over several months. Thinking of day 2 as a calibration period rather than a forecast of treatment is a more accurate read of what the evidence actually shows.

The most common day-2 experiences, and a misconception worth letting go

A belief that circulates online is that if you feel fine on day 2, the medicine is not working. That is not how semaglutide works. Tolerability varies enormously between individuals; some people sail through the first weeks with barely any nausea, while others find the adjustment harder. Neither experience predicts how much weight someone will lose over the course of treatment. The NHS semaglutide page lists the most common side effects across the prescribable schedule: nausea, vomiting, diarrhoea, constipation, indigestion, burping and fatigue. On day 2 specifically, reduced appetite is frequently noticed (sometimes quite noticeably) alongside mild nausea. For most people these effects are mild to moderate in intensity and begin to ease within a few days as the body adapts.

Practical steps that tend to help on day 2 include eating smaller portions, favouring bland foods over rich or fatty meals, staying well hydrated, and avoiding lying flat immediately after eating. None of these override your prescriber's guidance, and your Patient Information Leaflet covers them in detail. If nausea is uncomfortable rather than manageable, it is worth noting that the next dose increase on the prescribed schedule is usually four weeks away, there is time for your system to settle before anything changes. For a fuller picture of how each day in the first week tends to differ, the day-by-day Wegovy guide on our site takes you through the pattern.

Symptoms on day 2 that need medical attention

Most day-2 discomfort is unremarkable and self-limiting. Severe symptoms are different and need to be taken seriously. In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known, infrequent but potentially serious side effect of GLP-1 medicines including semaglutide. The warning sign to act on is severe stomach pain, particularly pain that is persistent rather than coming and going, and that radiates toward the back, with or without vomiting. That kind of symptom needs same-day medical assessment, not reassurance from a forum.

Other signs that warrant a call to your GP or 111 rather than waiting: signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing, a widespread rash), symptoms of significant dehydration from repeated vomiting (dizziness on standing, no urination), or any mood changes that feel unusual for you. Suspected side effects from any medicine can be reported directly to the MHRA via Yellow Card, it is a straightforward process and the data genuinely informs future safety guidance. Most people notice a shift as the week progresses, and our Wegovy day 4 page covers what typically changes by that point and why it often feels easier.

How day 2 fits into the broader Wegovy journey

It helps to hold day 2 in proportion. The STEP 1 trial found an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, but that result was built across months of slowly increasing doses, not a single eventful week. The early days are a small part of a long arc. Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition; those thresholds sit about 2.5 kg/m² lower for some ethnic backgrounds under UK guidance. The medicine is prescription-only, and every legitimate prescription follows a clinical assessment, a prescriber weighing your health history, current medicines, and any conditions that might affect how you respond.

For those considering treatment rather than already on it, a useful place to start is understanding how semaglutide works and what the full treatment pathway involves. If questions about cost come up (they usually do) a transparent breakdown of what private Wegovy treatment includes is on the Wegovy prices page. And if day 2 has raised questions you want to discuss with a prescriber, starting a free consultation means a GPhC-registered prescriber reviews your case the same day.